Form 8-K - Current report:
SEC Accession No. 0000929638-23-003305
Filing Date
2023-11-29
Accepted
2023-11-29 16:50:53
Documents
17
Period of Report
2023-11-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT a8k.htm   iXBRL 8-K 38514
2 exhibit10-1.htm EX-10.1 31477
3 exhibit10-2.htm EX-10.2 75363
4 exhibit99-1.htm EX-99.1 10328
9 engene_logo.jpg GRAPHIC 9375
  Complete submission text file 0000929638-23-003305.txt   387464

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA engn-20231127.xsd EX-101.SCH 4591
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE engn-20231127_def.xml EX-101.DEF 18194
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE engn-20231127_lab.xml EX-101.LAB 28281
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE engn-20231127_pre.xml EX-101.PRE 20436
11 EXTRACTED XBRL INSTANCE DOCUMENT a8k_htm.xml XML 6478
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 231453010
SIC: 2836 Biological Products, (No Diagnostic Substances)